Remission according to DAS28 (DAS28 <2.6) | Remission according to modified ARA criteria | |||||||
---|---|---|---|---|---|---|---|---|
Univariate | Multivariate | Univariate | Multivariate | |||||
OR | 95% CI | Adj. OR | 95% CI | OR | 95% CI | Adj. OR | 95% CI | |
DAS28 | 0.53 | 0.45–0.62 | 0.46 | 0.35–0.61 | 0.69 | 0.59–0.82 | ||
Propensity score (scale: 0 to 1)a | 0.86 | 0.80–0.93 | 0.89 | 0.80–0.99 | 0.92 | 0.85–1.00 | 0.84 | 0.75–0.94 |
Rheumatoid factor positive | 0.51 | 0.35–0.75 | 0.68 | 0.44–1.06 | ||||
ESRb | 0.75 | 0.68–0.82 | 0.92 | 0.85–1.00 | ||||
CRPb | 0.94 | 0.89–1.00 | 0.96 | 0.90–1.01 | ||||
Swollen joint count | 0.93 | 0.91–0.96 | 0.96 | 0.93–0.99 | ||||
Tender joint count | 0.94 | 0.92–0.97 | 1.05 | 1.01–1.09 | 0.94 | 0.92–0.97 | ||
FFbHb | 1.26 | 1.17–1.37 | 1.21 | 1.11–1.32 | 1.13 | 1.03–1.25 | ||
No. of previous DMARD | ||||||||
4 to 5 versus 2 to 3 | 0.68 | 0.47–0.97 | 0.74 | 0.50–1.10 | ||||
≥6 versus 2 to 3 | 0.47 | 0.24–0.91 | 0.53 | 0.26–1.10 | ||||
Female | 0.88 | 0.59–1.31 | 1.06 | 0.67–1.69 | ||||
Ageb | 0.68 | 0.59–0.78 | 0.74 | 0.62–0.87 | 0.72 | 0.62–0.84 | 0.72 | 0.61–0.85 |
Disease duration (years) | 0.98 | 0.96–1.00 | 0.99 | 0.96–1.00 | ||||
Disease duration ≤2 years versus >2 years | 1.86 | 0.97–3.58 | 0.81 | 0.32–2.09 | ||||
Any comorbidity yes versus no | 0.52 | 0.37–0.73 | 0.68 | 0.46–1.01 | ||||
Osteoporosis yes versus no | 0.38 | 0.23–0.61 | 0.51 | 0.30–0.87 | 0.69 | 0.44–1.10 | ||
BIOL versus CON | 1.08 | 0.73–1.59 | 1.95 | 1.20–3.19 | 1.35 | 0.85–2.13 | 2.05 | 1.19–3.52 |
Anti-TNF agents versus CON | 1.10 | 0.74–1.63 | 1.97 | 1.20–3.21 | 1.39 | 0.88–2.20 | 2.09 | 1.22–3.59 |
Anakinra versus CON | 0.71 | 0.26–1.91 | 1.66 | 0.56–4.91 | 0.68 | 0.20–2.36 | 1.19 | 0.33–4.34 |